Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Stanford University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Emory University
Emory University
NRG Oncology
University of Michigan Rogel Cancer Center
Ohio State University Comprehensive Cancer Center